N-Farnesyloxy-norcantharimide inhibits progression of human leukemic Jurkat T cells through regulation of mitogen-activated protein kinase and interleukin-2 production

Chang, Ming-Hong; Wu, Jin‐Yi; Liao, Hui-Fen; Chen, Yu-Jen; Kuo, Cheng‐Deng

doi:10.1097/cad.0000000000000284

Cited by 7 publications

(6 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can not only enhance the inhibitory effect on cancer cells, but also reduce side effects [177,178]. In addition, some other NCTD derivatives and liposomes, such as NOC15 (N-farnesyloxy-norcantharimide) [179] and SG-NCTD-LIP (NCTD-loaded liposomes modified with stearyl glycyrrhetinate) [176], also can effectively improve the anticancer activity and reduce the toxicity of NCTD. However, although these studies have shown that NCTD analogues have a very broad application prospect, most of the existing NCTD analogues have no obvious selectivity for tumors and targets.…”

Section: Discussionmentioning

confidence: 99%

Insight into norcantharidin, a small-molecule synthetic compound with potential multi-target anticancer activities

2020

View full text Add to dashboard Cite

Norcantharidin (NCTD) is a demethylated derivative of cantharidin, which is an anticancer active ingredient of traditional Chinese medicine, and is currently used clinically as a routine anti-cancer drug in China. Clarifying the anticancer effect and molecular mechanism of NCTD is critical for its clinical application. Here, we summarized the physiological, chemical, pharmacokinetic characteristics and clinical applications of NCTD. Besides, we mainly focus on its potential multi-target anticancer activities and underlying mechanisms, and discuss the problems existing in clinical application and scientific research of NCTD, so as to provide a potential anticancer therapeutic agent for human malignant tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Insight into norcantharidin, a small-molecule synthetic compound with potential multi-target anticancer activities

2020

View full text Add to dashboard Cite

show abstract

“…Jurkat cells are an immortalized line of human T lymphocyte cells of highly spherical shape with the diameter ranging from 10 to 16 µm, first derived from the peripheral blood of a 14-year-old boy suffering from T cell leukemia [33]. Jurkat cells can be transfected and can produce interleukin-2 (IL-2) [34,35]. Therefore, they can be used as the host to study T-cell receptor (TCR) signaling which are greatly related to adoptive cell therapy-a novel treatment of several advanced forms of cancer and many other researches on cancer treatments [36].…”

Section: Introductionmentioning

confidence: 99%

Determination of the Membrane Transport Properties of Jurkat Cells with a Microfluidic Device

Yang

Shu

et al. 2019

Micromachines

View full text Add to dashboard Cite

The Jurkat cell is an immortalized line of human acute lymphocyte leukemia cells that is widely used in the study of adoptive cell therapy, a novel treatment of several advanced forms of cancer. The ability to transport water and solutes across the cell membrane under different temperatures is an important factor for deciding the specific protocol for cryopreservation of the Jurkat cell. In this study we propose a comprehensive process for determination of membrane transport properties of Jurkat cell. using a novel microfluidic controlled single cell-trapping system. The osmotic behavior of an individual Jurkat cell to water and dimethyl sulfoxide (DMSO), a commonly used cryoprotective agent (CPA), under constant temperature, was recorded under a microscope utilizing the modified microfluidic system. The images of the Jurkat cell under osmotic change were processed to obtain a relationship between cell volume change and time. The experimental results were fitted using a two-parameter transport numeric model to calculate the Jurkat cell membrane permeability to water and DMSO at room temperature (22 °C). This model and the calculated parameters can help scientists optimize the cryopreservation protocol for any cell type with optimal cryoprotective agents and cooling rate for future experiments.

show abstract

“…The “net effect” has been devised to compare the net therapeutic effects of 2 anticancer drugs [ 19 ] so that the therapeutic effect of one anticancer drug relative to the other can be realized. Since the definition of “net effect” involves 2 drugs and 2 kinds of cell lines, it cannot be used to evaluate the therapeutic effect and toxicity of a single drug.…”

Section: Discussionmentioning

confidence: 99%

“…In our previous study, the anticancer activity ratio of drug X over drug Y toward cancer cells and the toxicity ratio of drug X over drug Y toward normal cells were defined as [ 19 ] …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparative assessment of therapeutic safety of norcantharidin, N-farnesyloxy-norcantharimide, and N-farnesyl-norcantharimide against Jurkat T cells relative to human normal lymphoblast

Chang

Wu²,

Liao

et al. 2016

Medicine

Self Cite

View full text Add to dashboard Cite

The therapeutic safety of an anticancer drug is one of the most important concerns of the physician treating the cancer patient. Half maximal inhibitory concentration (IC50) and hillslope are usually used to represent the strength and sensitivity of an anticancer drug on cancer cells. The therapeutic safety of the anticancer drug can be assessed by comparing the IC50 and hillslope of anticancer drugs on cancer cells relative to normal cells. Since there are situations where “more anticancer activity” implies “more toxicity,” the safety of an anticancer drug in these situations is hard to evaluate by using IC50 and hillslope alone. In a previous study, the “net effect” index was devised to represent the net therapeutic effects of one anticancer drug relative to the other. However, the therapeutic safety of one specific anticancer drug alone was not defined in the “net effect” index. This study introduced the “safety index (SI)” to quantify the degree of safety of an anticancer drug by using 4-parameter logistic model on cancer cells relative to normal cells. The therapeutic safety of norcantharidin (NCTD), N-farnesyloxy-norcantharimide (NOC15), and N-farnesyl-norcantharimide (NC15) in the treatment of Jurkat T cells relative to human normal lymphoblast was compared using the newly defined SI. We found that the SI of NOC15 and NC15 was significantly higher than that of NCTD, suggesting that both NOC15 and NC15 can damage more cancer cells and less normal cells than NCTD. We conclude that both NOC15 and NC15 are safer anticancer drugs than NCTD in the treatment of Jurkat T cells relative to human normal lymphoblast. The SI can be further applied to the screening, developments, and applications of anticancer drugs in the future.

show abstract

N-Farnesyloxy-norcantharimide inhibits progression of human leukemic Jurkat T cells through regulation of mitogen-activated protein kinase and interleukin-2 production

Cited by 7 publications

References 44 publications

Insight into norcantharidin, a small-molecule synthetic compound with potential multi-target anticancer activities

Insight into norcantharidin, a small-molecule synthetic compound with potential multi-target anticancer activities

Determination of the Membrane Transport Properties of Jurkat Cells with a Microfluidic Device

Comparative assessment of therapeutic safety of norcantharidin, N-farnesyloxy-norcantharimide, and N-farnesyl-norcantharimide against Jurkat T cells relative to human normal lymphoblast

Contact Info

Product

Resources

About